360biolabs
Melbourne, Australia· Est.
Australian‑based CRO delivering end‑to‑end bioanalytical services for early‑phase clinical development.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Australian‑based CRO delivering end‑to‑end bioanalytical services for early‑phase clinical development.
Infectious DiseasesImmunologyOncologyVaccines
Technology Platform
Integrated bioanalytical platform employing LC‑MS/MS, ELISA/ECL, flow cytometry and microneutralization assays, compliant with GLP/GCP/ISO standards for PK/PD, immunogenicity, and biomarker analysis.
Opportunities
Leveraging Australia’s fast regulatory pathway and R&D tax incentives to attract early‑phase sponsors, and expanding assay capabilities for emerging modalities such as mRNA and cell therapies.
Risk Factors
Intense competition from larger global CROs and the need to continuously meet evolving regulatory and quality standards across multiple jurisdictions.
Competitive Landscape
Competes with Charles River, WuXi AppTec, Labcorp and PPD; differentiates through Australian regulatory advantages, a tightly integrated global lab network, and specialized infectious‑disease assay expertise.